The largest database of trusted experimental protocols

7 protocols using mk 1775

1

Cytotoxicity Assay of Tumor Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
HeLa, DLD-1, BT-549, HCC1937, KB2P1.21 and KB2P1.21R1 tumour cell lines were plated in 96-wells plates. BT-549 cells were pre-treated with 1 μg ml−1 doxycycline for 48 h. HeLa were plated at 2,000 cells per well, DLD-1 cells at 5,000 cells per well, BT-549 and HCC1937 cells at 1,000 cells per well, and KB2P1.21 and KB2P1.21R1 were plated at 1,200 cells per well. Cells were allowed to attach for 3 or 24 h and were treated with indicated concentrations of olaparib, MK-1775, or MK4827 (all from Axon Medchem, Groningen, the Netherlands) for 3 or 4 days. Methyl-thiazol tetrazolium (MTT) was added to cells at a concentration of 5 mg ml−1 for 4 h, after which culture medium was removed and formazan crystals were dissolved in DMSO. Absorbance values were determined using a Bio‐Rad benchmark III Biorad microtiter spectrophotometer at a wavelength of 520 nm. Proliferation was determined as the relative decrease in signal compared to DMSO-treated cells. Unless mentioned otherwise, statistical significance was tested using Student’s t-test.
+ Open protocol
+ Expand
2

Synergistic Effects of dl922-947 and AZD1775 on MM Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
MM cells were seeded in 96-well plates 24 h before treatment with dl922-947 and AZD1775 (MK1775, purchased from Axon Medchem), both alone and in combination at various concentrations in a constant ratio. Five days after treatment, cells were fixed with 50% (v/v) trichloroacetic acid and stained with 0.4% (w/v) SRB in 1% (v/v) acetic acid, following the manufacturer’s instructions. Synergism, additivity, or antagonism were determined through isobologram analysis using the CompuSyn software 1.0 (ComboSyn, Inc., Paramus, NJ, USA). Combination index (CI) values were also calculated by the CompuSyn software, which uses the Chou–Talalay method. CI < 1 indicates synergism, CI = 1 additivity, and CI > 1 antagonism. The r value represents the linear correlation coefficient of the median effect plot, which indicates the conformity of the data to the mass action law.
+ Open protocol
+ Expand
3

Inhibitor Sources for Cell Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
Inhibitors were purchased from the following distributors: AdooQ BioScience (Irvine, CA, USA; Aurora A inhibitor I, BI‐2536, epothilone A, MK‐1775 and VX‐680); Axon Medchem (Reston, VA, USA; SPL‐B); Focus Biomolecules (Plymouth Meeting, PA, USA; Latrunculin A); MedChemExpress (Princeton, NJ, USA; PF‐2771); Selleck Chemicals (Houston, TX, USA; GSK‐923295); Sigma‐Aldrich (Importazole, RO‐3306, and S‐trityl‐l‐cysteine); Thermo Fisher Scientific (Waltham, MA, USA; Colcemid (KaryoMAX Colcemid)); Calbiochem (San Diego, California CA, USA; Etoposide); LKT Laboratories (St. Paul, MN, USA; Vinblastine); Tocris Bioscience, (Bristol, UK; Monastrol); Wako (Cytochalasin B, daunorubicin, doxorubicin, nocodazole and paclitaxel).
+ Open protocol
+ Expand
4

Evaluating WEE1 Inhibitor MK-1775 Effects

Check if the same lab product or an alternative is used in the 5 most similar protocols
The small molecule WEE1 inhibitor, MK-1775, was purchased from Axon Medchem (Groninberg, Netherlands) or synthesized by us. Dimethyl sulfoxide (DMSO) was used to reconstitute the drug and subsequent aliquots were stored in a desiccator at -20°C. An equivalent amount of DMSO for the highest concentration of drug was used for each experiment as a vehicle control.
+ Open protocol
+ Expand
5

Cell Cycle Regulation Assay Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following chemical inhibitors were used at the indicated concentrations, unless stated otherwise, WEE1 inhibitor MK-1775 (250nM, Axon Medchem), CDK1 inhibitor RO-3306 (10μM; Tocris), hydroxyurea (HU; 3mM), mitomycin C (MMC, 100nM; both from Sigma-Aldrich).
Antibodies used were phospho-Histone H3-Ser10 (pH3; 06-570, Upstate), phospho-Histone-H2AX-Ser139 (05-636, Upstate; 9718, Cell Signaling Technology), β-actin (A5441), β-Tubulin (T4026, both from Sigma-Aldrich), CHK1 (sc-8408, Santa Cruz Biotechnology), MYT1 (4282), MRE11 (4895), Ezrin (3145; all from Cell Signalling Technology), BRIP1 (NB100-416), FANCD2 (NB100-182), 53BP1 (NB100-304; all from Novus Biologicals).
+ Open protocol
+ Expand
6

Cytotoxicity Assay for Drug Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cisplatin was purchased from Sigma Aldrich; paclitaxel from ChemieTek; olaparib from LC Laboratories; VE822, MK1775 and KU55933 from Axon Medchem; THZ1 and THZ1 hydrochloride were from Insight Biotechnology Limited; ET-743 from PharmaMar and PF-00477736 from Pfizer. For cytotoxicity experiments, cell lines were seeded in 96-well plates and were treated after 48 hours with different concentrations of the drugs. After 72 hours cell viability was examined with the MTS assay (Promega) and absorbance was acquired using a plate reader (Infinite M200, TECAN). Drug concentrations inhibiting growth in 50% of the cells (IC50s) were calculated for each cell line, with the interpolation method.
+ Open protocol
+ Expand
7

Antibody panel for cell analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following commercial antibodies were used at the indicated concentrations for Western blot (WB) and immunofluorescence (IF): a-tubulin (DM1A, Sigma-Aldrich; Cat#T6199, 1:1000 IF), Ki67 (Abcam; Cat#ab15580; 1:1000 IF), E-cadherin (DECMA-1, GeneTex; Cat#GTX11512, 1:1000 IF), aE-catenin (Enzo; Cat#ALX-804-101-C100, 1:500 IF), a-catenin (Sigma-Aldrich; Cat#C2081, 1:500 IF), Phospho-Histone H3 Ser10 (3H10, Millipore; Cat#05-806, 1:1000 IF), Wee1 (D10D2, Cell signaling; Cat#13084, 1:500 IF, 1:1000 WB), a-actinin (BM-75.2, Sigma-Aldrich; Cat#A5044, 1:500 IF), phospho-Cdk1 Tyr15 (Cell signaling; Cat#9111, 1:250 IF), Vinculin (hVIN-1, Sigma-Aldrich; Cat#V9131, 1:250 IF), Cdk1 (PSTAIR; Millipore; Cat#06-923; 1:500), Cdk1 (POH1, Cell signaling; Cat#9116, 1:250 IF), p130CAS (BD Biosciences; Cat#610271, 1:3000 WB), phospho-Histone H2A.X Ser139 (JBW301; Millipore; Cat#05-636, 1:1000 IF).
The following reagents were used at the indicated concentrations: MK-1775 (Axon Medchem; Cat#1494, 500 nM), Calyculin A (Enzo; Cat#BML-EI192-0100, 10 ng/mL), MG132 (Santa Cruz; Cat#sc-201270, 5mM), Thapsigargin (Sigma-Aldrich; Cat#T9033, 1 mM), Yoda (Tocris; Cat#5586, 10 mM).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!